Guidance on pharmacovigilance procedures in the event of a no-deal Brexit

This guidance summarises our approach to pharmacovigilance in the event of no-deal Brexit.

This publication was withdrawn on

For current information on pharmacovigilance procedures see European Medicines Agency: Post-authorisation

Published 18 March 2019
Last updated 9 October 2019 + show all updates
  1. Major changes to content, including two new sections (9 and 10).

  2. Change of text within Stay up to date box.

  3. First published.